Evidence map›Paper›PMID 40241092›Full record

ArticleOrphanet journal of rare diseases2025

Self-reported access to specialty clinics and receipt of health surveillance among U.S. patients with neurofibromatosis 1: a national survey.

Vanessa L Merker, Yidan Ma, Lori B Chibnik, Heather B Radtke, Kate Kelts, Kaleb Yohay, Nicole J Ullrich, Scott R Plotkin, Justin T Jordan

Registry-linked trialAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06262113 (A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06262113 nacompletednot on this map

A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1

TypeinterventionalSponsorMassachusetts General HospitalRan2024 to 2026Enrolled294ConditionsNeurofibromatosis 1ArmsLetters about NF1 Care (Content Type 1), Letters about NF1 Care (Content Type 2)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vanessa L MerkerDepartment of Neurology, Massachusetts General Hospital, Boston, MA, 02144, USA. vmerker@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-4542-5227
Yidan MaMGH Biostatistics, Massachusetts General Hospital, Boston, MA, 02144, USA.
Lori B ChibnikDepartment of Neurology, Massachusetts General Hospital, Boston, MA, 02144, USA.
Heather B RadtkeChildren's Tumor Foundation, New York, NY, 10017, USA.
Kate KeltsChildren's Tumor Foundation, New York, NY, 10017, USA.
Kaleb YohayDepartment of Neurology, NYU Langone Health, New York, NY, 10017, USA.
Nicole J UllrichDepartment of Neurology, Boston Children's Hospital, Boston, MA, 02115, USA.
Scott R Plotkin *Department of Neurology, Massachusetts General Hospital, Boston, MA, 02144, USA.
Justin T Jordan *Department of Neurology, Massachusetts General Hospital, Boston, MA, 02144, USA.

Funding

Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI Hisashi Umemori · 2021 to 2026
$9.4M
NICHD NIH HHS P50 HD105351
6 · The paper itself

Abstract

backgroundNeurofibromatosis 1 (NF1) is a rare, neurogenetic disorder predisposing individuals to multiple tumors and other issues requiring expert care and regular health monitoring. We sought to assess U.S. patients' access to specialized NF1 clinics and receipt of evidence-informed health surveillance.

methodsAn online survey was distributed to NF Registry participants in May 2021. Rate of NF1 clinic attendance and self-reported receipt of health surveillance amongst NF Registry participants was estimated using inverse propensity scores. Differences in these outcomes based on participant demographics were assessed using weighted logistic regression and robust linear regression, respectively.

results322 individuals responded (160 adults, 162 parents; 4.7% overall response rate). We estimate that 51.7% of children and 35.6% of adults attend NF1 clinics. Younger children were more likely to attend an NF1 clinic, as were adults living in urban areas, with a college degree or higher, or with a household income ≥ $130,000 (all ps < 0.05). Completion rates for each individual health surveillance evaluation ranged from 41 to 79% for children and 33-61% for adults. Higher rates of recommended evaluations were reported by both adults and children who attend a specialized NF1 clinic, non-Hispanic White adults, and adults with commercial or Medicare insurance (all ps < 0.05).

conclusionsAdults with NF1 experience significant sociodemographic disparities in care, and patients of all ages attending NF1 specialty clinics receive more recommended health surveillance. Given the limited access to specialty NF clinics, quality improvement efforts are needed to increase access for underserved adults and improve provision of recommended health surveillance outside specialty clinics.

Indexed as

Health Services AccessibilityNeurofibromatosis 1AdolescentAdultAgedChildChild, PreschoolFemaleHumansMaleMiddle AgedSelf ReportSurveys and QuestionnairesUnited StatesYoung AdultHealthcare disparitiesNeurofibromatosis 1Practice guidelinesRare diseases

Identifiers

PMID40241092
PMCPMC12004880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.